GlaxoSmithKline Ebitda from 2010 to 2024
| GLAXO Stock | 2,444 30.80 1.28% |
EBITDA | First Reported 2017-06-30 | Previous Quarter 2.3 B | Current Value 3.6 B | Quarterly Volatility 1.9 B |
Check GlaxoSmithKline Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 391.6 M, Interest Expense of 9.8 M or Selling General Administrative of 462 M, as well as many indicators such as . GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline Pharmaceuticals Valuation or Volatility modules.
GlaxoSmithKline | Ebitda |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline Pharmaceuticals financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline Pharmaceuticals security.